

FREEDOM OF INFORMATION REQUEST RF24-132

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

Avelumab + Axitinib	8
Axinitib	3
Cabozantinib	19
Everolimus	5
Lenvantinib + Everolimus	0
Nivolumab monotherapy	14
Nivolumab + Cabozantinib	0
Nivolumab + Ipilimumab	1
Pazopanib	4
Pembrolizumab monotherapy	11
Pembrolizumab + Lenvatinib	0
Pembrolizumab + Axitinib	0
Radiotherapy only	0
Sunitinib	2
Temsirolimus	0
Tivozanib	1
Other active systemic anti-cancer therapy	0
Palliative care only	Unknown*

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

Cobimetinib	0
Dabrafenib	1
Dabrafenib + Trametinib	13
Dacarbazine	0
Denosumab	3
Encorafenib + Binimetinib	6
Ipilimumab monotherapy	0
Ipilimumab + Nivolumab	7
Nivolumab monotherapy	13
Nivolumab + Relatlimab	0
Pembrolizumab	30
Trametinib	0
Vemurafenib	0
Vemurafenib + Cobimetinib	0
Other active systemic anti-cancer therapy	1
Palliative care only	Unknown*

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

Ipilimumab monotherapy	0
Ipilimumab + Nivolumab	7
Nivolumab monotherapy	10
Nivolumab + Relatlimab	0
Pembrolizumab	15
Any Targeted Therapy (Dabrafenib /Dabrafenib AND	18
Trametinib /Encorafenib AND	
Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND	
Cobimetinib)	
Other active systemic anti-cancer therapy	4
Palliative care only	Unknown*

^{*}EKHUFT regret we are unable to answer this question as this data is not recorded in ARIA e-prescribing pharmacy system.

(DATE OF RESPONSE: 19 FEBRUARY 2024)

